R&D channel feed

Re­gen­eron re­veals da­ta be­hind de­pri­or­i­tized BC­MA/CD3 bis­pe­cif­ic: #AACR23

3 years ago

GSK stopped two UTI an­tibi­ot­ic tri­als ear­ly af­ter meet­ing ef­fi­ca­cy end­points. Now it’s shar­ing the full da­ta

3 years ago

Roche's com­bo ther­a­py re­duces risk of liv­er can­cer re­turn­ing but rais­es safe­ty ques­tions: #AACR23

3 years ago

As­traZeneca lines up com­pe­ti­tion with Mer­ck in lung can­cer be­fore and af­ter surgery: #AACR23

3 years ago

Mer­ck­'s Keytru­da-chemo re­duces risk of death from bil­iary tract can­cer by 17%: #AACR23

3 years ago

Mod­er­na and Mer­ck pre­pare for PhI­II tri­al of can­cer vac­cine, and an ex­pan­sion to lung can­cer: #AACR23

3 years ago
Pharma

MindMed gains af­ter in­ves­ti­ga­tor tri­al of LSD shows im­pact on ma­jor de­pres­sion

3 years ago

Swedish biotech Guard Ther­a­peu­tics to stop PhII af­ter in­ter­im re­view

3 years ago

Tonix cuts in­ter­im analy­ses of two tri­als, halves en­roll­ment in one

3 years ago

Up­dat­ed: New da­ta from a mas­sive Parkin­son’s tri­al could lead to break­throughs in drug de­vel­op­ment

3 years ago

Ahead of ad­comm, FDA backs Rex­ul­ti for first ap­proval for ag­i­ta­tion as­so­ci­at­ed with Alzheimer’s de­men­tia

3 years ago
Pharma

As­traZeneca ends dai­ly GLP-1/glucagon tri­als in switch to week­ly in­jec­tion op­tion for NASH, oth­er in­di­ca­tions

3 years ago
Pharma

Take­da tak­ing mag­ni­fy­ing glass to non-vi­ral gene ther­a­py pro­grams as Carmine pact ends

3 years ago
Cell/Gene Tx

Mer­ck KGaA's BTK in­hibitor hit by par­tial clin­i­cal hold over safe­ty con­cern, but PhI­II read­out un­af­fect­ed

3 years ago
FDA+

Sci­ence-whiz twins backed by a16z bring Func­tion On­col­o­gy out of stealth

3 years ago
Financing

How ARPA-H's new hub-and-spoke mod­el will cre­ate a na­tion­wide re­search net­work

3 years ago
Pharma

Four years lat­er, FDA fi­nal­izes guid­ance on risk-based mon­i­tor­ing of clin­i­cal tri­als

3 years ago
FDA+

Preprint man­date? BioRx­iv and medRx­iv founders call on White House to en­sure ear­ly ac­cess to gov­ern­ment-fund­ed re­search

3 years ago

Up­dat­ed: Mod­er­na: Not enough flu cas­es in PhI­II tri­al yet to tell ef­fi­ca­cy

3 years ago

Take­da joins forces with small pri­vate biotech for pre­clin­i­cal Alzheimer's re­search

3 years ago
Deals

Chi­nook paus­es PhI kid­ney dis­ease tri­al af­ter se­ri­ous ad­verse event

3 years ago

ARCH-backed HI-Bio touts ear­ly da­ta from two tri­als for rare kid­ney dis­ease

3 years ago

Agency ex­pands video gam­ing prac­tice with new pod­cast on 'gamechang­er­s' for phar­ma and health­care

3 years ago

Medicare spend­ing on CLL drugs sky­rock­ets from $254M to $3.7B in 7 years, JA­MA study finds

3 years ago
First page Previous page 91929394959697 Next page Last page
A service from the Financial Times